- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Gastroenterology Research and Practice
Volume 2012 (2012), Article ID 243524, 7 pages
Molecular Biologic Approach to the Diagnosis of Pancreatic Carcinoma Using Specimens Obtained by EUS-Guided Fine Needle Aspiration
Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa Prefecture, Takamatsu 761-0793, Japan
Received 30 May 2012; Revised 13 August 2012; Accepted 15 October 2012
Academic Editor: Grazyna Rydzewska
Copyright © 2012 Kiyohito Kato et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- W. Hosoda, T. Takagi, N. Mizuno et al., “Diagnostic approach to pancreatic tumors with the specimens of endoscopic ultrasound-guided fine needle aspiration,” Pathology International, vol. 60, no. 5, pp. 358–364, 2010.
- K. Yamao, A. Sawaki, N. Mizuno, Y. Shimizu, Y. Yatabe, and T. Koshikawa, “Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNAB): past, present, and future,” Journal of Gastroenterology, vol. 40, no. 11, pp. 1013–1023, 2005.
- S. Yoshinaga, H. Suzuki, I. Oda, and Y. Saito, “Role of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for diagnosis of solid pancreatic masses,” Digestive Endoscopy, vol. 23, no. 1, pp. 29–33, 2011.
- C. Almoguera, D. Shibata, K. Forrester, J. Martin, N. Arnheim, and M. Perucho, “Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes,” Cell, vol. 53, no. 4, pp. 549–554, 1988.
- M. A. Collins, F. Bednar, Y. Zhang et al., “Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice,” Journal of Clinical Investigation, vol. 122, no. 2, pp. 639–653, 2012.
- M. Tada, Y. Komatsu, T. Kawabe et al., “Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor,” American Journal of Gastroenterology, vol. 97, no. 9, pp. 2263–2270, 2002.
- K. Takahashi, K. Yamao, K. Okubo et al., “Differential diagnosis of pancreatic cancer and focal pancreatitis by using EUS-guided FNA,” Gastrointestinal Endoscopy, vol. 61, no. 1, pp. 76–79, 2005.
- F. Maluf-Filho, A. Kumar, R. Gerhardt et al., “Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass,” Journal of Clinical Gastroenterology, vol. 41, no. 10, pp. 906–910, 2007.
- X. Wang, J. Gao, Y. Ren et al., “Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis,” American Journal of Gastroenterology, vol. 106, no. 12, pp. 2104–2111, 2011.
- B. Bournet, A. Souque, P. Senesse et al., “Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis,” Endoscopy, vol. 41, no. 6, pp. 552–557, 2009.
- S. Reicher, F. Z. Boyar, M. Albitar et al., “Fluorescence in situ hybridization and K-ras analyses improve diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses,” Pancreas, vol. 40, no. 7, pp. 1057–1062, 2011.
- M. Hollstein, D. Sidransky, B. Vogelstein, and C. C. Harris, “p53 mutations in human cancers,” Science, vol. 253, no. 5015, pp. 49–53, 1991.
- C. M. Barton, S. L. Staddon, C. M. Hughes et al., “Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer,” British Journal of Cancer, vol. 64, no. 6, pp. 1076–1082, 1991.
- R. J. C. Slebos, J. A. Hoppin, P. E. Tolbert et al., “K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study,” Cancer Epidemiology Biomarkers and Prevention, vol. 9, no. 11, pp. 1223–1232, 2000.
- M. S. Redston, C. Caldas, A. B. Seymour et al., “p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions,” Cancer Research, vol. 54, no. 11, pp. 3025–3033, 1994.
- T. Itoi, K. Takei, A. Sofuni et al., “Immunohistochemical analysis of p53 and MIB-1 in tissue specimens obtained from endoscopic ultrasonography-guided fine needle aspiration biopsy for the diagnosis of solid pancreatic masses,” Oncology Reports, vol. 13, no. 2, pp. 229–234, 2005.
- A. W. Jahng, S. Reicher, D. Chung, et al., “Staining for p53 and Ki-67 increases the sensitivity of EUS-FNA to detect pancreatic malignancy,” World Journal of Gastrointestinal Endoscopy, vol. 2, no. 11, pp. 362–368, 2010.
- C. Caldas, S. A. Hahn, L. T. da Costa et al., “Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma,” Nature Genetics, vol. 8, no. 1, pp. 27–32, 1994.
- D. Bartsch, D. W. Shevlin, W. S. Tung, O. Kisker, S. A. Wells Jr., and P. J. Goodfellow, “Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas,” Genes Chromosomes and Cancer, vol. 14, no. 3, pp. 189–195, 1995.
- C. Salek, L. Benesova, M. Zavoral et al., “Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer,” World Journal of Gastroenterology, vol. 13, no. 27, pp. 3714–3720, 2007.
- A. Maitra and R. H. Hruban, “Pancreatic cancer,” Annual Review of Pathology, vol. 3, pp. 157–188, 2008.
- J. Ringel and M. Löhr, “The MUC gene family: their role in diagnosis and early detection of pancreatic cancer,” Molecular Cancer, vol. 2, article 9, 2003.
- M. I. Filipe, “Mucins and gastrointestinal malignancy. A new approach to the interpretation of biopsies,” Acta Medica Portuguesa, vol. 1, no. 3, pp. 351–365, 1979.
- M. I. Filipe, “Mucins in the human gastrointestinal epithelium: a review,” Investigative and Cell Pathology, vol. 2, no. 3, pp. 195–216, 1979.
- T. A. Giorgadze, H. Peterman, Z. W. Baloch et al., “Diagnostic utility of mucin profile in fine-needle aspiration specimens of the pancreas: an immunohistochemical study with surgical pathology correlation,” Cancer, vol. 108, no. 3, pp. 186–197, 2006.
- Y. Wang, J. Gao, Z. Li, Z. Jin, Y. Gong, and X. Man, “Diagnostic value of mucins (MUC1, MUC2 and MUC5AC) expression profile in endoscopic ultrasound-guided fine-needle aspiration specimens of the pancreas,” International Journal of Cancer, vol. 121, no. 12, pp. 2716–2722, 2007.
- S. Carrara, M. G. Cangi, P. G. Arcidiacono et al., “Mucin expression pattern in pancreatic diseases: findings from EUS-guided fine-needle aspiration biopsies,” American Journal of Gastroenterology, vol. 106, no. 7, pp. 1359–1363, 2011.
- S. E. Dowen, T. Crnogorac-Jurcevic, R. Gangeswaran et al., “Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer,” American Journal of Pathology, vol. 166, no. 1, pp. 81–92, 2005.
- T. Arumugam and C. D. Logsdon, “S100P: a novel therapeutic target for cancer,” Amino Acids, vol. 41, no. 4, pp. 893–899, 2011.
- H. J. Whiteman, M. E. Weeks, S. E. Dowen et al., “The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D,” Cancer Research, vol. 67, no. 18, pp. 8633–8642, 2007.
- K. Ohuchida, K. Mizumoto, T. Egami et al., “S100P is an early developmental marker of pancreatic carcinogenesis,” Clinical Cancer Research, vol. 12, no. 18, pp. 5411–5416, 2006.
- T. Arumugam, D. M. Simeone, K. van Golen, and C. D. Logsdon, “S100P promotes pancreatic cancer growth, survival, and invasion,” Clinical Cancer Research, vol. 11, no. 15, pp. 5356–5364, 2005.
- T. Crnogorac-Jurcevic, E. Missiaglia, E. Blaveri et al., “Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent,” Journal of Pathology, vol. 201, no. 1, pp. 63–74, 2003.
- O. Kosarac, H. Takei, Q. J. Zhai, M. R. Schwartz, and D. R. Mody, “S100P and XIAP expression in pancreatic ductal adenocarcinoma: potential novel biomarkers as a diagnostic adjunct to fine needle aspiration cytology,” Acta Cytologica, vol. 55, no. 2, pp. 142–148, 2011.
- D. C. Dim, F. Jiang, Q. Qiu et al., “The usefulness of S100P, mesothelin,fascin, prostate stem cell antigen, and 14-3-3 sigma in diagnosing pancreatic adenocarcinoma in cytological specimens obtained by endoscopic ultrasound guided fine-needle aspiration,” Diagnostic Cytopathology. In press.
- H. Deng, J. Shi, M. Wilkerson, S. Meschter, W. Dupree, and F. Lin, “Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens,” American Journal of Clinical Pathology, vol. 129, no. 1, pp. 81–88, 2008.
- K. Kato, J. Gong, H. Iwama et al., “The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo,” Molecular Cancer Therapeutics, vol. 11, no. 3, pp. 549–560, 2012.
- M. Preis, T. B. Gardner, S. R. Gordon et al., “MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma,” Clinical Cancer Research, vol. 17, no. 17, pp. 5812–5821, 2011.
- S. Jones, X. Zhang, D. W. Parsons et al., “Core signaling pathways in human pancreatic cancers revealed by global genomic analyses,” Science, vol. 321, no. 5897, pp. 1801–1806, 2008.
- M. Yamada, S. Sekine, R. Ogawa et al., “Frequent activating GNAS mutations in villous adenoma of the colorectum,” Journal of Pathology, vol. 228, no. 1, pp. 113–118, 2012.
- M. Kanda, H. Matthaei, J. Wu et al., “Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia,” Gastroenterology, vol. 142, no. 4, pp. 730.e9–733.e9, 2012.
- F. Schönleben, W. Qiu, K. C. Bruckman et al., “BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas,” Cancer Letters, vol. 249, no. 2, pp. 242–248, 2007.
- A. C. Henke, C. S. Jensen, and M. B. Cohen, “Cytologic diagnosis of adenocarcinoma in biliary and pancreatic duct brushings,” Advances in Anatomic Pathology, vol. 9, no. 5, pp. 301–308, 2002.
- O. David, L. Green, V. Reddy et al., “Pancreatic masses: a multi-institutional study of 364 fine-needle aspiration biopsies with histopathologic correlation,” Diagnostic Cytopathology, vol. 19, no. 6, pp. 423–427, 1998.
- S. Mori-Iwamoto, Y. Kuramitsu, S. Ryozawa et al., “Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine,” International Journal of Oncology, vol. 31, no. 6, pp. 1345–1350, 2007.
- T. Itoi, A. Sofuni, N. Fukushima et al., “Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas,” Journal of Gastroenterology, vol. 42, no. 5, pp. 389–394, 2007.
- R. Ashida, B. Nakata, M. Shigekawa et al., “Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer,” Journal of Experimental and Clinical Cancer Research, vol. 28, no. 1, article 83, 2009.